title: The impact of pharmacogenomics on the management of cardiac disease.
abstract: Pharmacogenomics promises to help maximize efficacy and minimize adverse drug reactions. It could have a significant impact on the treatment of cardiovascular disease, the leading cause of death in the United States. The past decade has seen pharmacogenomics move from study of a candidate gene to genome-wide approaches, with the development of a series of pharmacogenetic tests. However, many barriers need to be overcome for cardiovascular pharmacogenomics to have its promised clinical impact.
authors.affiliation: Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota, USA. pereira.naveen@mayo.edu
authors.forename: N L
authors.initials: NL
authors.lastname: Pereira
authors.forename: R M
authors.initials: RM
authors.lastname: Weinshilboum
mesh_terms: D002318:Cardiovascular Diseases / Q000453:epidemiology* / Q000517:prevention & control*; D014943:Global Health; D015438:Health Behavior; D006801:Humans